From the BlogSubscribe Now

Indi Molecular Raises $11.5 in Series A Round

BioCentury (June 29, 2017)
[Read more…]

Indi Molecular raises $11.5M in series A to back new synthetic class in research, imaging

BioWorld Medtech (June 29, 2017)
[Read more…]

Indi Molecular Raises $11.5M Series A to Accelerate PCC Platform Development

CULVER CITY, CA – June 28, 2017 – Indi Molecular, an emerging life sciences company that is developing a novel, synthetic class of binders with antibody-like properties called protein catalyzed capture agents (PCCs), announced today that it has raised a $11.5 million Series-A financing led by M Ventures (Merck Ventures BV, Amsterdam, the Netherlands, a subsidiary of Merck KGaA, Darmstadt Germany known as M Ventures in the United States and Canada), the strategic corporate venture capital arm of Merck KGaA Darmstadt, Germany; Legend Capital, a venture capital/private equity fund based in Beijing; Sabey Corporation; and existing investors including Asset Management Ventures. As part of the financing, Dr. Andreas Jurgeit from Merck Ventures and Dr. Darren Cai from Legend Capital will join Indi Molecular’s board. The Series-A proceeds will be used to establish a high throughput PCC discovery platform and to advance existing leads in PET immuno-oncology imaging to clinical stage.
[Read more…]

Angewandte Chemie Paper Demonstrates PCC Ability to Enter Cells and Inhibit Botulinum Neurotoxin with Remarkable Binding Ability and Specificity

Angewandte Chemie (April 29, 2015)
[Read more…]

Landmark Indi Molecular® Publication in Nature Chemistry Suggests PCC Binding Technology May Enable Therapeutics for Previously Undruggable Targets Based on Mutations of A Single Amino Acid

CULVER CITY, CA – (April 13, 2015) – Researchers at Caltech and Indi Molecular announced today a landmark publication in Nature Chemistry suggesting that the PCC (protein catalyzed capture) agent binding technology may enable the creation of highly specific therapeutics for targets that have long been considered undruggable. PCC technology was invented at Caltech and is being commercialized by Indi Molecular.
[Read more…]

GenomeWeb – Indi Molecular Inks PCC Development Deal with Sigma, But Main Focus Now on Therapeutics

GenomeWeb | Dec 19, 2014 | Adam Bonislawski
“As we have talked to pharmaceutical companies, it has become very clear that their interest is in super-binding molecules that can target very low abundance therapeutic targets, things that are really hard to reach with a monoclonal,” said Albert Luderer, CEO.
[Read more…]

Indi Molecular® and Sigma-Aldrich® Establish Collaboration to Explore Use of PCC Technology in Biological Tools

Press Release | 17 December 2014
CULVER CITY, CA — Indi Molecular, the maker of a synthetic replacement for monoclonal antibodies, today announced that it has entered into a co-development agreement with Sigma-Aldrich to explore the use of Indi Molecular’s PCC technology with Sigma-Aldrich’s line of biological tools. PCC (protein catalyzed capture) agent technology is a breakthrough process that produces synthetic peptide molecules capable of binding interactions that are equivalent or superior to molecular antibodies. Current systems employ antibody-based biological tools that are used to capture proteins and enable highly sensitive detection. The joint research and development project will explore the use of PCCs to specifically interact with proteins.

[Read more…]

Dr. Doug Fisher to Speak at Life Sciences Summit

Dr. Doug Fisher, to Speak at Life Sciences Summit
October 29, 2014 | New York, NY |

BioCentury – Indi Molecular: Building better binders

BioCentury | 31 March 2014 | Emily Cukier-Meisner
“We’ve been able to create a completely synthetic approach to building binding
molecules,” said Albert Luderer, CEO

Indi Molecular Expands Seed Round to $1.8 Million with Additional $300 from Asset Management Ventures

CULVER CITY, CA — (December 10, 2013) — Indi Molecular, which pioneered a synthetic replacement for antibodies, today announced that it has raised an additional $300,000 from a new investor, Asset Management Ventures. With this investment, the company has expanded its seed round to a total of $1.8 million. The round was led by InterWest Partners and joined by several angel investors. The funds are being used to further develop PCC (protein catalyzed capture) agent technology: a breakthrough process that produces synthetic peptide molecules capable of binding interactions that are equivalent or superior to molecular antibodies. The company also announced that it has published three new papers in recent weeks, appearing in Angewandte Chemie, PLOS One and ACS Nano. All three papers were written in collaboration with researchers at the California Institute of Technology (Caltech), with the goal of furthering the development of PCC technology.

[Read more…]